Outcomes of androgen replacement therapy in adult male hypogonadism: Recommendations from the Italian Society of Endocrinology

Journal of Endocrinological Investigation

Volumn 38, Issue 1, 2015, Pages 103-112

  Isidori, A M ^a   Balercia, G ^b   Calogero, A E ^c   Corona, G ^d   Ferlin, A ^e   Francavilla, S ^f   Santi, D ^g   Maggi, M ^h  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d BELLARIA HOSPITAL   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF L'AQUILA   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; ANDROGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ARTICLE; BODY COMPOSITION; BONE DENSITY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DEPRESSION; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; ENDOCRINOLOGIST; ENDOCRINOLOGY; ERYTHEMA; ERYTHROCYTOSIS; GLYCEMIC CONTROL; HEMATOCRIT; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPOGONADISM; HYPOXEMIA; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; METABOLIC DISORDER; MUSCLE MASS; OSTEOPOROSIS; POLYCYTHEMIA; PRACTICE GUIDELINE; PROSTATE CANCER; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SEXUAL FUNCTION; SIDE EFFECT; SLEEP DISORDERED BREATHING; SYMPTOM; TESTOSTERONE BLOOD LEVEL; THROMBOSIS; TREATMENT OUTCOME; ADULT; BLOOD; ITALY; MALE; STANDARDS;

ADULT; ANDROGENS; ENDOCRINOLOGY; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; ITALY; MALE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 84923918582     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-014-0155-9     Document Type: Article

References (63)

1. Corona G, Rastrelli G, Maggi M (2013) Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab 27(4):557-579
2. Huang G, Bhasin S, Tang ER et al (2013) Effect of testosterone administration on liver fat in older men with mobility limitation: results from a randomized controlled trial. J Gerontol A Biol Sci Med Sci 68(8):954-959
3. Tan WS, Low WY, Ng CJ et al (2013) Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU Int 111(7):1130-1140
4. Caminiti G, Volterrani M, Iellamo F et al (2009) Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 54(10):919-927
5. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH (2004) The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89(7):3313-3318
6. Page ST, Amory JK, Bowman FD et al (2005) Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90(3):1502-1510
7. Tenover JS (1992) Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 75(4):1092-1098
8. Francomano D, Bruzziches R, Barbaro G, Lenzi A, Aversa A (2014) Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest 37(4):401-411
9. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P (2013) Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med 10(6):1612-1627
10. Jones TH, Arver S, Behre HM et al (2011) Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 34(4):828-837
11. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F (2010) Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 73(5):602-612
12. Srinivas-Shankar U, Roberts SA, Connolly MJ et al (2010) Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 95(2):639-650
13. Kapoor D, Goodwin E, Channer KS, Jones TH (2006) Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154(6):899-906
14. Francomano D, Lenzi A, Aversa A (2014) Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol 2014:527470
15. Isidori AM, Lenzi A (2005) Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest 28(3 Suppl):14-22
16. Ferlin A, Selice R, Carraro U, Foresta C (2013) Testicular function and bone metabolism-beyond testosterone. Nat Rev Endocrinol 9(9):548-554
17. Francis RM (1999) The effects of testosterone on osteoporosis in men. Clin Endocrinol (Oxf) 50(4):411-414
18. Aversa A, Bruzziches R, Francomano D et al (2012) Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male 15(2):96-102
19. Isidori AM, Giannetta E, Greco EA et al (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 63(3):280-293
20. Kenny AM, Kleppinger A, Annis K et al (2010) Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 58(6):1134-1143
21. Tracz MJ, Sideras K, Bolona ER et al (2006) Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 91(6):2011-2016
22. Tirabassi G, Delli MN, Gioia A, Biagioli A, Lenzi A, Balercia G (2014) Effects of testosterone replacement therapy on bone metabolism in male post-surgical hypogonadotropic hypogonadism: focus on the role of androgen receptor CAG polymorphism. J Endocrinol Invest 37(4):393-400
23. Amory JK, Watts NB, Easley KA et al (2004) Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89(2):503-510
24. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R (2008) Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 20(4):378-387
25. Corona G, Rastrelli G, Balercia G, Sforza A, Forti G, Maggi M (2012) Testosterone and cardiovascular risk in patients with erectile dysfunction. J Endocrinol Invest 35(9):809-816
26. Isidori AM, Giannetta E, Pozza C, Bonifacio V, Isidori A (2005) Androgens, cardiovascular disease and osteoporosis. J Endocrinol Invest 28(10 Suppl):73-79
27. Calof OM, Singh AB, Lee ML et al (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60(11):1451-1457
28. Fernandez-Balsells MM, Murad MH, Lane M et al (2010) Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95(6):2560-2575
29. Haddad RM, Kennedy CC, Caples SM et al (2007) Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 82(1):29-39
30. Xu L, Freeman G, Cowling BJ, Schooling CM (2013) Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 11:108
31. Corona G, Maseroli E, Rastrelli G et al (2014) Cardiovascular risk associated with testosterone boosting medications. Expert Opin Drug Safety (in press)
32. Ioannidis JP (2009) Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med 169(19):1737-1739
33. Huhtaniemi I, Forti G (2011) Male late-onset hypogonadism: pathogenesis, diagnosis and treatment. Nat Rev Urol 8(6):335-344
34. Radicioni AF, Ferlin A, Balercia G et al (2010) Consensus statement on diagnosis and clinical management of Klinefelter syndrome. J Endocrinol Invest 33(11):839-850
35. Wu FC, Tajar A, Beynon JM et al (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363(2):123-135
36. Isidori AM, Corona G, Aversa A et al (2014) The SIAMS-ED trial: a national, independent, multicentre study on cardiometabolic and hormonal impairment of men with erectile dysfunction treated with vardenafil. Int J Endocrinol 2014:858715
37. Bolona ER, Uraga MV, Haddad RM et al (2007) Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 82(1):20-28
38. Corona G, Isidori AM, Buvat J et al (2014) Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med 11(6):1577-1592
39. Isidori AM, Buvat J, Corona G et al (2014) A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol 65(1):99-112
40. Condorelli RA, Calogero AE, La VS (2013) Different profile of endothelial cell apoptosis in patients with Klinefelter's syndrome. J Endocrinol Invest 36(2):84-91
41. Jannini EA, Isidori AM, Aversa A, Lenzi A, Althof SE (2013) Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions. J Sex Med 10(10):2359-2369
42. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M (2012) How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl 14(2):251-259
43. Johnson JM, Nachtigall LB, Stern TA (2013) The effect of testosterone levels on mood in men: a review. Psychosomatics 54(6):509-514
44. Amanatkar HR, Chibnall JT, Seo BW, Manepalli JN, Grossberg GT (2014) Impact of exogenous testosterone on mood: a systematic review and meta-analysis of randomized placebo-controlled trials. Ann Clin Psychiatry 26(1):19-32
45. Cotter AG, Powderly WG (2011) Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. Best Pract Res Clin Endocrinol Metab 25(3):501-515
46. Rochira V, Zirilli L, Orlando G et al (2011) Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS ONE 6(12):e28512
47. Bhasin S, Cunningham GR, Hayes FJ et al (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95(6):2536-2559
48. Buvat J, Maggi M, Guay A, Torres LO (2013) Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med 10(1):245-284
49. Corona G, Baldi E, Maggi M (2011) Androgen regulation of prostate cancer: where are we now? J Endocrinol Invest 34(3):232-243
50. Marks LS, Mazer NA, Mostaghel E et al (2006) Effect of testosterone replacement therapy on prostate tissue in men with lateonset hypogonadism: a randomized controlled trial. JAMA 296(19):2351-2361
51. Merza Z, Blumsohn A, Mah PM et al (2006) Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Int J Androl 29(3):381-391
52. Snyder PJ, Peachey H, Hannoush P et al (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84(6):1966-1972
53. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R (2003) AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 88(6):2673-2681
54. Aversa A, Bruzziches R, Francomano D et al (2010) Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results froma 24 month, randomized, double-blind, placebo-controlled study. J Sex Med 7(10):3495-3503
55. Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G (2004) Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 63(4):641-646
56. Shahidi NT (1973) Androgens and erythropoiesis. N Engl J Med 289(2):72-80
57. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D (1995) Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc 43(8):899-901
58. Hajjar RR, Kaiser FE, Morley JE (1997) Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 82(11):3793-3796
59. Morley JE, Perry HM III, Kaiser FE et al (1993) Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 41(2):149-152
60. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C (2006) Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 367(9520):1412-1420
61. Matsumoto AM, Sandblom RE, Schoene RB et al (1985) Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (Oxf) 22(6):713-721
62. Snyder PJ, Peachey H, Hannoush P et al (1999) Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84(8):2647-2653
63. Rolf C, Knie U, Lemmnitz G, Nieschlag E (2002) Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol (Oxf) 56(5):637-641